**REPORT DOCUMENTATION PAGE**

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and preparing the data needed, and completing and reviewing the collection of information. Send comments regarding this estimate of any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Service Directorates (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information that does not display a currently valid OMB control number.

Please do not return your form to the above organization.

1. **REPORT DATE (DD-MM-YYYY)**
   - 08/27/2017

2. **REPORT TYPE**
   - Poster

3. **DATES COVERED (From - To)**
   - 08/27/2017-08/30/2017

4. **TITLE AND SUBTITLE**
   - Benzodiazepine Use Among Low Back Pain Patients Concurrently Prescribed Opioids in the Military Health System

5. **AUTHOR(S)**
   - Maj Joseph Maddry

6. **PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**
   - 59th Clinical Research Division
   - 1100 Wiltford Hall Loop, Bldg. 4430
   - JBSA-Lackland, TX 78236-9908
   - 210-292-7141

7. **SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)**
   - 59th Clinical Research Division
   - 1100 Wiltford Hall Loop, Bldg. 4430
   - JBSA-Lackland, TX 78236-9908
   - 210-292-7141

8. **PERFORMING ORGANIZATION REPORT NUMBER**
   - 17356

9. **DISTRIBUTION/AVAILABILITY STATEMENT**
   - Approved for public release. Distribution is unlimited.

10. **SUPPLEMENTARY NOTES**

11. **ABSTRACT**

12. **SUBJECT TERMS**

13. **SECURITY CLASSIFICATION OF:**
    - a. REPORT
    - b. ABSTRACT
    - c. THIS PAGE

14. **LIMITATION OF ABSTRACT**

15. **NUMBER OF PAGES**

16. **NAME OF RESPONSIBLE PERSON**
    - Clarice Longoria

17. **TELEPHONE NUMBER (include area code)**
    - 210-292-7141
Benzodiazepine Use Among Low Back Pain Patients Concurrently Prescribed Opioids in the Military Health System

Megan Curtis, MA; William Kazanis, MS; Claudina Tami, BS; Mary Jo Pugh, PhD; RN; Don McGear, PhD; Erin P. Finley, PhD, MPH; Maj General K. Maddry, MD, Col (S) Vikhyat S. Baboura, MD, Col David Carnahan, MD, MSC; Jennifer Sharpe Potter, PhD, MPH

1The University of Texas Health Science Center at San Antonio, 2South Texas Veterans Health Care System, 3Emergency Department, Brooke Army Medical Center, 45th Medical Wing Science & Technology Cell, 5San Antonio Uniformed Services Health Education Consortium, 6University of Colorado School of Medicine, 7Colorado Air National Guard, 8Defense Health Agency

Introduction

Pain is a common complaint among returning deployed service members, with 25% reporting at least one pain-related injury during Basic Combat Training. Opioids are commonly prescribed to patients with low back pain (LBP) in the military health system. Concurrently prescribed opioids and benzodiazepines (benzos) pose safety risks for patients, including over-sedation and overdose.

Despite abuse liability and long-term safety concerns of opioids for chronic pain, there are high rates (16-38%) of concurrent opioid and benzo prescribing. These high-risk prescribing patterns have contributed to the fatal opioid overdose epidemic.

There is scant evidence regarding opioid and benzos prescribing practices among Active Duty Service Member (ADSM) with LBP. It is important to understand factors associated with benzos use in this population to identify those most vulnerable to safety issues.

Objective: To investigate factors associated with benzos concurrently prescribed with opioids among ADSM with LBP, who started their first opioid episode in 2012 or 2013.

Methods

Participants

- ADSM not deployed in theater
- ADSM eligible for TRICARE coverage for at least 11 months in a calendar year of 2012 or 2013 who filled their first opioid prescription and were also prescribed a benzo during an opioid episode

Data Analysis

- A retrospective cohort analysis was conducted on de-identified administrative data between 2012 and 2013
- Data was from the Department of Defense M2 DataMart which provided prescription information and Johns Hopkins ACG system Enhanced Diagnosis Clusters
- A logistic regression was conducted to determine factors associated with concurrent prescribing of opioids and benzos among ADSM with LBP

Results

The cohort was 42,253 ADSM who received opioids with a LBP diagnosis. Out of the cohort, 36,301 were prescribed opioids only and 5,952 concurrently received opioids and benzos.

Table 1. Prescription and psychosocial characteristics of ADSM

<table>
<thead>
<tr>
<th>Variables</th>
<th>Opioid Only N (%)</th>
<th>Opioid and Benzodiazepine N (%)</th>
<th>Total N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>28,016 (22.08)</td>
<td>1,050 (17.04)</td>
<td>29,066 (21.49)</td>
</tr>
<tr>
<td>Male</td>
<td>14,237 (11.92)</td>
<td>4,902 (8.23)</td>
<td>19,139 (14.18)</td>
</tr>
<tr>
<td>Sponsor Service</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Army</td>
<td>18,734 (51.61)</td>
<td>3,118 (52.39)</td>
<td>21,852 (51.72)</td>
</tr>
<tr>
<td>Air Force</td>
<td>7,747 (21.34)</td>
<td>1,067 (17.93)</td>
<td>8,814 (20.86)</td>
</tr>
<tr>
<td>Marine Corps</td>
<td>3,609 (9.94)</td>
<td>892 (15.63)</td>
<td>4,401 (10.18)</td>
</tr>
<tr>
<td>Navy</td>
<td>6,210 (17.77)</td>
<td>1,075 (18.06)</td>
<td>7,285 (17.24)</td>
</tr>
<tr>
<td>Average MME*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 to 20</td>
<td>9,087 (24.98)</td>
<td>1,554 (26.11)</td>
<td>10,641 (25.14)</td>
</tr>
<tr>
<td>21 to 50</td>
<td>19,766 (54.46)</td>
<td>3,383 (56.94)</td>
<td>23,149 (54.79)</td>
</tr>
<tr>
<td>51 to 100</td>
<td>6,926 (19.08)</td>
<td>931 (15.84)</td>
<td>7,857 (18.80)</td>
</tr>
<tr>
<td>&gt; 100</td>
<td>540 (1.49)</td>
<td>84 (1.41)</td>
<td>624 (1.48)</td>
</tr>
<tr>
<td>LA/ER Opioid*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 60 days</td>
<td>5,266 (14.51)</td>
<td>1,957 (32.88)</td>
<td>7,223 (17.09)</td>
</tr>
<tr>
<td>&gt; 60 days</td>
<td>31,036 (85.49)</td>
<td>3,995 (67.12)</td>
<td>35,030 (82.91)</td>
</tr>
</tbody>
</table>

Psychosocial

- Substance use 1,218 (3.35) 381 (9.40) 1,599 (3.78)
- Anxiety 6,688 (18.42) 1,481 (24.88) 8,169 (19.33)
- Antidepressants 2,282 (6.29) 1,047 (17.59) 3,330 (7.88)

Note: Average MME = total opioid prescriptions / total days supplied. LA/ER = long acting / extended release opioid prescription.

Conclusion

Consistent with CDC guidelines, concurrently prescribed opioids and benzos may pose a greater risk for adverse events than being prescribed an opioid alone. As indicated by our logistic regression, those with long term opioid use, polypharmacy (e.g. antidepressant prescriptions), and polymorbidities (e.g. substance use or anxiety) were more likely to be concurrently prescribed an opioid and benzo.

The polymorbidities of LBP mental health, and substance use highlight the need for a biopsychosocial approach to pain. The complexity of this population suggests additional strategies are needed to appropriately address patients' substance use and mental health status. The results are consistent with previous findings among both US veteran and civilian populations. To our knowledge, this is among the first to examine factors associated with benzo use in a ADSM with LBP receiving opioids.